Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACT: Colchicine therapy after PCI in troponin-positive acute coronary syndrome
KCT0009444Phase 4Not yet recruiting
- Sponsor
- Biotronik
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of colchicine in acute coronary syndrome (ACS), sponsored by Biotronik. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on KCT0009444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009444.